Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 122

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 122
---
 rendering these services. The nature of the services provided for each category is described following the table.

Fee Category 2024  2023 Audit Fees (1) $237,500  $161,488 Audit-Related Fees ‒  ‒  Tax Fees (2)  -  $60,000 Total $237,500  $221,448 

_________________ 

(1) Audit fees include fees for professional services rendered for the audit of our annual statements, quarterly reviews, consents and assistance with and review of documents filed with the SEC.

(2) Tax fees include fees for professional services rendered for tax compliance, tax advice and tax planning.

 65Table of Contents

PART IV

Item 15. Exhibits, Financial Statements and Schedules

(a) List of documents filed as part of this report:

1. Financial Statements (see “Financial Statements and Supplementary Data” at Item 8 and incorporated herein by reference)

2. Financial Statement Schedules (Schedules to the Financial Statements have been omitted because the information required to be set forth therein is not applicable or is shown in the accompanying Financial Statements or notes thereto)

3. Exhibits

The following is a list of exhibits filed as part of this Annual Report:

ExhibitNumber Exhibit DescriptionFiled HerewithIncorporation by ReferenceFormExhibitFiling Date3.1Fourth Amended and Restated Certificate of Incorporation of the Company, as amended [Restated for SEC filing purposes only]x   3.2Amended and Restated Bylaws of the Company S-13.412/06/164.1Specimen Certificate representing shares of common stock of the Company S-14.111/21/164.2Certificate of Designations of Series A Convertible Preferred Stock 8-K4.112/11/194.3Form of Warrant issued in December 2019 Series A Convertible Preferred Stock Offering 8-K4.212/11/194.4Certificate of Designations of Series B Convertible Preferred Stock 8-K4.112/26/194.5Form of Warrant issued in December 2019 Series B Convertible Preferred Stock Offering 8-K4.212/26/194.6Certificate of Designations of Series C Preferred Stock 8-K3.109/27/224.7Form of Warrant issued in April 2023 Underwritten Public Offering S-14.